TargeGen, Inc., is a privately held biopharmaceutical company based in San Diego. The Company combines a focus on vascular biology with expertise in small molecule medicinal chemistry. TargeGen® develops small-molecule multi target kinase inhibitors designed to reduce disease related increases in vascular permeability (edema), vascular proliferation (angiogenesis) and inflammation. These biological processes are associated with a broad range of human diseases including ischemic disorders, eye diseases (macular degeneration, diabetic macular edema, diabetic retinopathy) and various forms of cancer.
TargeGen, Inc., is a privately held biopharmaceutical company based in San Diego. The Company combines a focus on vascular biology with expertise in small molecule medicinal chemistry. TargeGen® develops small-molecule multi target kinase inhibitors designed to reduce disease related increases in vascular permeability (edema), vascular proliferation (angiogenesis) and inflammation. These biological processes are associated with a broad range of human diseases including ischemic disorders, eye diseases (macular degeneration, diabetic macular edema, diabetic retinopathy) and various forms of cancer.
